Sign up to receive Dana-Farber Spotlight, our email newsletter.View the current issueSubscribe nowUnsubscribe from mailings
Ellen BerlinDirector of Media Relations617firstname.lastname@example.org
Molly McHaleAssociate Director of Media Relations617email@example.com
Rachel Freedman commented on targeted treatments – those that attack a specific
characteristic of a cancer strain – becoming the norm in breast cancer care.
Dr. Eric Winer served as chair for a panel that developed the second international guidelines for management of advanced breast cancer.
Dr. Toni Choueiri led a study that found patients with non–clear cell renal cell carcinoma, PD-L1 positivity is associated with worse clinical outcomes, including a shorter overall survival and time to recurrence.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: